Let’s talk about my PFWA awards ballot, featuring tough decisions at MVP, defensive player of the year and defensive rookie ...

Another military man in the drugs business was Edward Robinson Squibb ... With its hepatitis C drugs, Gilead faced huge amounts of controversy over the initial costs of its therapies, although ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and, now, more deeply than before, into inflammation, penning a major $1.7 billion deal ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn from Morgan Stanley upgraded the rating on the stock ...

(Reuters) - Gilead Sciences (NASDAQ:GILD) said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish ...

CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and ...

In the latest market close, Gilead Sciences (GILD) reached $92.38, with a +1.52% movement compared to the previous day. The stock lagged the S&P 500's daily gain of 1.83%. Meanwhile, the Dow gained 1.